| Michael James Frizinia, RPH | |
|
404 Main St, Ansonia, CT 06401-2307 | |
| (203) 926-1508 | |
| Not Available |
| Full Name | Michael James Frizinia |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 404 Main St, Ansonia, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396024915 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 5912 (Connecticut) | Primary |
| 183500000X | Pharmacist | 20202 (Florida) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Michael James Frizinia, RPH 84 Big Horn Rd, Shelton, CT 06484-1855 Ph: (203) 257-4393 | Michael James Frizinia, RPH 404 Main St, Ansonia, CT 06401-2307 Ph: (203) 926-1508 |
News Archive
Lansing Community College – after two years of planning – is set to launch a unique medical program that will give a well-earned boost to men and women who served as military medics.
A new article has been published in Cellular and Molecular Lifesciences, which focuses on the connection between host factors and the worsening of the COVID-19. Further, the impact of the virus on the host's microbiome and secondary infection has also been studied.
University Hospitals Harrington Heart & Vascular Institute researchers Muhammad Panhwar, MD, and Mahazarin Ginwalla, MD, recently concluded a study of more than 22 million patients that suggests a strong connection between Inflammatory Bowel Disease (IBD) and the development of heart disease and heart attacks.
Men's Health Network calls on Congress to ensure that healthcare reform does not override the prostate cancer testing benefit currently required of insurance companies in 37 states.
Cell Therapeutics, Inc. reported today preliminary cardiac safety results from a North American randomized phase II trial which substituted pixantrone for doxorubicin in the standard CHOP-R regimen. Called PIX203, the randomized trial compared CPOP-R directly to CHOP-R in the 1st line treatment of high risk patients with diffuse large B cell non-Hodgkin's lymphoma (DLBCL, NHL).
› Verified 5 days ago
Anna Kucharczyk, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 24 Pershing Dr, Ansonia, CT 06401 Phone: 203-735-7837 | |
Julia Marie Paterson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 24 Pershing Dr # 36, Ansonia, CT 06401 Phone: 203-735-7837 | |
Melissa Bonanno, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 24 Pershing Dr, Ansonia, CT 06401 Phone: 203-735-7837 | |
Michael G Deotte, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 24 Pershing Dr, Ansonia, CT 06401 Phone: 203-735-7837 | |
Paul I Odiwo, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 404 Main St, Ansonia, CT 06401 Phone: 203-734-3152 | |
Mohamed Khatib, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 24 Pershing Dr, Ansonia, CT 06401 Phone: 203-735-7837 | |
Dr. Jamie Durkin, PHARM-D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 24 Pershing Dr, Ansonia, CT 06401 Phone: 203-735-7837 Fax: 203-735-3080 |